|
|
| Digging Into Manufacturing Priorities For Viral Vectors | Article | Novartis Contract Manufacturing | Addressing the complexities of viral vector manufacturing through strategic internalization, advanced technologies, and regulatory excellence is crucial for the future of gene therapies. |
|
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Investment manager BlackRock gathered powerful investors to discuss along with government officials the nation’s physical and economic backbone. The Infrastructure Summit clarified the biopharma industry including CDMOs are in a battle for investments and infrastructure. Analysis from Chief Editor Louis Garguilo. | |
|
|
|
Does Biotech Need More Government Funding — Or A New Business Model? | By Louis Garguilo, chief editor, Outsourced Pharma | Should government financing appreciably recede – whether through policy shifts, budget pressures, or ideological bent – what would happen to the biotech business model? To ascertain such a question, first we must look at the fundamentals of the existing model and then understand investors (and service providers) better. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
|
| Translating Stem Cell Programs To GMP | Webinar | Landmark Bio | A detailed exploration of challenges in advancing stem cell programs to GMP, highlighting strategies to control variability, strengthen process design, and support reliable clinical‑stage manufacturing. |
|
|
|
| Capital Constraints In CDMO & Pharma M&A | Q&A | Vector BioMed | Capital constraints are reshaping CDMO and pharma strategies, driving selective M&A, prioritizing partnerships, and enforcing financial discipline amid tighter investment conditions. |
|
|
| Unlocking The Next Wave Of Cancer Vaccines | Webinar | Cytiva | Assimilate how advanced ionizable LNP formulations and scalable manufacturing strategies can accelerate the development and clinical translation of personalized cancer vaccines. |
|
|
|
|
|
|
|
| Connect With Outsourced Pharma: |
|
|
|
